The suppressive effect of mangiferin with exercise on blood lipids in type 2 diabetes
Open accessAbstract
The effect of mangiferin (MF) with exercise on bood lipids was studied in KK-Ay mice, an animal model of type 2 diabetes. MF (30 mg/kg) reduced the blood cholesterol (p<0.05) and triglyceride level (p<0.01) of KK-Ay mice with exercise 2 weeks after oral administration when compared with the control group. Diabetes also often has elevated lipid levels. Therefore, it may be that MF has beneficial effects on hyperlipidemia in type 2 diabetes.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mangiferin exerts significant antidiabetic, antihyperlipidemic and antiatherogenic effects in diabetic rat models.
“Similarly, Muruganandan et al (28), Miura et al (29,30) and Suman et al (31) verified that mangiferin exerted significant antidiabetic, antihyperlipidemic and antiatherogenic effects in diabetic rat models.”
From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [29]
The Discussion reports that mangiferin with exercise reduced cholesterol and triglycerides in diabetic KK-Ay mice and describes antidiabetic activity in a preliminary study. The Materials section identifies the animals as mice, not rats. This paper does not report an antiatherogenic effect, and its principal lipid finding concerns mangiferin combined with exercise, not mangiferin alone. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 1
- Nakamura M., Proc. Jpn. Acad., 38, 348-352 (1962).
Cited by
Sorted by citations
Mangiferin: An effective therapeutic agent against several disorders (Review)
Du, S., Liu, H., Lei, T., Xie, X., Wang, H., He, X., Tong, R., & Wang, Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9529 · Cited by 139 · see citing works
“Similarly, Muruganandan et al (28), Miura et al (29,30) and Suman et al (31) verified that mangiferin exerted significant antidiabetic, antihyperlipidemic and antiatherogenic effects in diabetic rat models.”
Niu, Y., Li, S., Na, L., Feng, R., Liu, L., Li, Y., & Sun, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030782 · Cited by 116 · see citing works
Na, L., Zhang, Q., Jiang, S., Du, S., Zhang, W., Li, Y., Sun, C., & Niu, Y. (2015) · Scientific Reports · doi:10.1038/srep10344 · Cited by 74 · see citing works
UV/vis, 1H, and 13C NMR spectroscopic studies to determine mangiferin pKa values
Gómez-Zaleta, B., Ramírez-Silva, M. T., Gutiérrez, A., González-Vergara, E., Güizado-Rodríguez, M., & Rojas-Hernández, A. (2006) · Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2005.09.009 · Cited by 64 · see citing works
Acevedo, L. M., Raya, A. I., Martínez-Moreno, J. M., Aguilera–Tejero, E., & Rivero, J.-L. L. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173028 · Cited by 24 · see citing works
Alsaedi, A. Q., Nader, M. A., El-Kashef, D. H., & Abdelmageed, M. E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572758 · Cited by 5 · see citing works
- Authors
- MIURA, T., IWAMOTO, N., KATO, M., ICHIKI, H., KUBO, M., KOMATSU, Y., ISHIDA, T., OKADA, M., & TANIGAWA, K.
- Affiliations
- Suzuka University of Medical Science (JP)
- Tsumura (Japan) (JP)
- Venue
- Biological & Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2001
- Volume
- 24
- Issue
- 9
- Pages
- 1091-1092
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W2013652436
- Cited by
- 71
- References
- 0
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 5 · 2014: 10 · 2013: 5 · 2012: 3
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Biological and Pharmaceutical Bulletin (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Natural Compound Pharmacology Studies
- Keywords
- mangiferin, physical activity, serum lipids, type 2 diabetes, hyperlipidemia, serum cholesterol, triglycerides, KK-Ay mice, animal models of diabetes
- MeSH terms
- Animals, Hypolipidemic Agents, Cholesterol, Diabetes Mellitus, Type 2, Physical Exertion, Hypoglycemic Agents, Lipids, Male, Mice, Inbred Strains, Triglycerides, Xanthenes, Xanthones, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
